Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1914 1
1926 1
1944 1
1946 1
1948 2
1953 1
1954 1
1955 1
1956 1
1957 2
1958 1
1959 2
1960 2
1963 2
1964 5
1965 1
1966 2
1967 5
1968 5
1969 6
1970 9
1971 7
1972 13
1973 11
1974 7
1975 12
1976 10
1977 13
1978 18
1979 12
1980 20
1981 37
1982 32
1983 33
1984 16
1985 21
1986 31
1987 33
1988 27
1989 28
1990 24
1991 25
1992 32
1993 31
1994 30
1995 21
1996 35
1997 32
1998 25
1999 19
2000 35
2001 29
2002 32
2003 38
2004 50
2005 43
2006 61
2007 39
2008 53
2009 46
2010 46
2011 57
2012 66
2013 65
2014 61
2015 57
2016 70
2017 58
2018 74
2019 83
2020 86
2021 107
2022 93
2023 80

Text availability

Article attribute

Article type

Publication date

Search Results

1,955 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Blauvelt A, et al. Among authors: simpson el. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. JAMA Dermatol. 2021. PMID: 34347860 Free PMC article. Clinical Trial.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T, Simpson EL, Silverberg JI, Thaçi D, Paul C, Pink AE, Kataoka Y, Chu CY, DiBonaventura M, Rojo R, Antinew J, Ionita I, Sinclair R, Forman S, Zdybski J, Biswas P, Malhotra B, Zhang F, Valdez H; JADE COMPARE Investigators. Bieber T, et al. Among authors: simpson el. N Engl J Med. 2021 Mar 25;384(12):1101-1112. doi: 10.1056/NEJMoa2019380. N Engl J Med. 2021. PMID: 33761207 Clinical Trial.
Understanding osteosarcomas.
Simpson E, Brown HL. Simpson E, et al. JAAPA. 2018 Aug;31(8):15-19. doi: 10.1097/01.JAA.0000541477.24116.8d. JAAPA. 2018. PMID: 29979330 Review.
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Wollenberg A, et al. Among authors: simpson el. Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30. Br J Dermatol. 2021. PMID: 33000465 Free PMC article. Clinical Trial.
Bone Marrow Transplantation 1957-2019.
Simpson E, Dazzi F. Simpson E, et al. Front Immunol. 2019 Jun 5;10:1246. doi: 10.3389/fimmu.2019.01246. eCollection 2019. Front Immunol. 2019. PMID: 31231381 Free PMC article. Review.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, Soong W, Gonzalez ME, Schneider LC, Sidbury R, Lockshin B, Meltzer S, Wang Z, Mannent LP, Amin N, Sun Y, Laws E, Akinlade B, Dillon M, Kosloski MP, Kamal MA, Dubost-Brama A, Patel N, Weinreich DM, Yancopoulos GD, O'Malley JT, Bansal A; participating investigators. Paller AS, et al. Among authors: simpson el. Lancet. 2022 Sep 17;400(10356):908-919. doi: 10.1016/S0140-6736(22)01539-2. Lancet. 2022. PMID: 36116481 Clinical Trial.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. Among authors: simpson el. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders.
Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, Tofte S, Dunn JD, Feldman SR, Clark AR, Schwartz G, Eichenfield LF. Paller A, et al. Among authors: simpson el. Am J Clin Dermatol. 2018 Dec;19(6):821-838. doi: 10.1007/s40257-018-0383-4. Am J Clin Dermatol. 2018. PMID: 30168085 Review.
1,955 results